A phase I clinical trial assessing ADCT-212
Latest Information Update: 04 Mar 2023
At a glance
- Drugs ADCT 212 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
Most Recent Events
- 28 Feb 2023 According to an ADC Therapeutics media release, the company plans to initiate this study in 1H 2024.
- 15 Nov 2022 New trial record
- 08 Nov 2022 According to ADC Therapeutics media release, the company is progressing toward IND filing and initiation of Phase 1 trial in 2023